@article {Beer:November 2006:0007-1048:392,
	author = "Beer, Tomasz M.",
	author = "Venner, Peter M.",
	author = "Ryan, Christopher W.",
	author = "Petrylak, Daniel P.",
	author = "Chatta, Gurkamal",
	author = "Dean Ruether, J.",
	author = "Chi, Kim N.",
	author = "Curd, John G.",
	author = "DeLoughery, Thomas G.",
	title = "High dose calcitriol may reduce thrombosis in cancer patients",
	journal = "British Journal of Haematology",
	volume = "135",
	year = "November 2006",
	abstract = "Summary <P></P>The incidence of venous and arterial thrombosis in a placebo-controlled randomised trial of DN-101 (high dose calcitriol) with docetaxel <I>versus</I> docetaxel was compared. Of the 13 thrombotic events observed in the 250 patients enroled in this study, two occurred in DN-101 and 11 in placebo-treated patients (<I>P</I>&#8201;=&#8201;0&#183;01). This difference remained significant after adjustment for baseline history of thrombosis, atrial fibrillation and use of anti-thrombotic agents. <I>In vitro</I> and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans.",
	pages = "392-394(3)",
	url = "http://www.ingentaconnect.com/content/bsc/bjh/2006/00000135/00000003/art00019"
	doi = "doi:10.1111/j.1365-2141.2006.06322.x"
}